FINDEX (3649) Fundamentals 2026 — P/E 16.7x, Revenue Analysis | SniperIQ
FINDEX (3649) is a JP-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of ¥20.6B, trading at ¥845.00 on the JPX. This SniperIQ fundamentals page covers FINDEX's valuation (P/E 16.7x, P/B 3.7x), profitability (net margin 20.2%), revenue (¥6.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is FINDEX's market cap?
FINDEX (3649) has a market capitalization of approximately ¥20.6B, trading at ¥845.00 on the JPX. Market cap moves with the live share price.
What is FINDEX's P/E ratio?
FINDEX's trailing twelve-month P/E ratio is 16.7x, with a price-to-book (P/B) of 3.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is FINDEX?
FINDEX runs a net profit margin of 20.2%, a gross margin of 65.8%, and an operating margin of 28.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does FINDEX generate?
FINDEX reported revenue of ¥6.1B for fiscal year 2025, with net income of ¥1.3B and earnings per share (EPS) of 50.07. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does FINDEX pay a dividend?
FINDEX offers a trailing dividend yield of about 3.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is FINDEX financially healthy?
FINDEX carries a debt-to-equity ratio of 0.00x and a current ratio of 4.00x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is FINDEX a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For FINDEX (3649) the key facts are: market cap ¥20.6B, P/E 16.7x, revenue ¥6.1B, 52-week range 717-1011. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track FINDEX's full fundamentals live
Get FINDEX's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.